Study of the Anti-tumoral Immune Response

Study of the Anti-tumoral Immune Response T Cells Cluster of Differentiation 4 (TCD4): Proof of the Concept in Breast Cancer and Glioma

This study evaluates the frequency of the spontaneous T cells specific CD4 answers of tumoral antigens breast cancer and glioma.

Inclusion Criteria:

• Performance status 0,1 or 2
• breast cancer or glioma
• Arm glioma: patients without anti-tumoral treatment
• Arm breast cancer: inclusion before treatment
• Arm breast cancer HER2: patients with current therapy

Exclusion Criteria:

• Psychiatric disease compromising the understanding of the information or the realization of the study
• vulnerable People according to the law (minors, adults under protection, private persons of freedom ...)
• Unaffiliated People to the Social Security
• People being for the period of exclusion from another study
• Life expectancy estimated unless 3 months.
• For patients in Arm glioma: patients having already begun a systematic treatment.
• For patients with a breast cancer: patient already under current therapy